Differential response of human glioblastoma cell lines to combined camptothecin and ionizing radiation treatment

Cancer Biology and Therapy

Volumn 7, Issue 3, 2008, Pages 364-373

  Djuzenova, Cholpon S ^a   Güttler, Teresa ^a   Berger, Sabrina ^a   Katzer, Astrid ^a   Flentje, Michael ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cell cycle; Colony forming assay; Double strand breaks; Histone H2AX

Indexed keywords

C 9911; CAMPTOTHECIN; CASPASE; CASPASE 3; DNA TOPOISOMERASE; DOUBLE STRANDED DNA; HISTONE H2AX; PROTEIN P53; RAD50 PROTEIN; SURVIVIN;

ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE PROGRESSION; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG EFFECT; DRUG RESPONSE; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; PROTEIN EXPRESSION;

EID: 45349106252     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.3.5363     Document Type: Article

References (40)

1. Walker MD, Alexander Jr E, Hunt WE, MacCarty CS, Mahaley Jr MS, Mealey Jr J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial. J Neurosurg 1978; 49:333-43.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96.
3. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas: A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983; 52:997-1007.
4. Hofer S, Herrmann R. Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineage. J Cancer Res Clin Oncol 2001; 127:91-5.
5. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol) 2007; 19:397-417.
6. Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 2001; 41:53-77.
7. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49:5077-82.
8. Holm C, Covey JM, Kerrigan D, Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 1989; 49:6365-8.
9. Wang JC. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev 2002; 3:430-41.
10. Wong ET, Berkenblit A. The role of topotecan in the treatment of brain metastases. Oncologist 2004; 9:68-79.
11. Gerrits CJ, de Jonge MJ, Schellens JH, Stoter G, Verweij J. Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development. Br J Cancer 1997; 76:952-62.
12. Kim JH, Kim SH, Kolozsvary A, Khil MS. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys 1992; 22:515-8.
13. Mattern MR, Hofmann GA, McCabe FL, Johnson RK. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 1991; 51:5813-6.
14. Chen AY, Chou R, Shih SJ, Lau D, Gandara D. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs. Crit Rev Oncol Hematol 2004; 50:11-9.
15. Lamond JP, Wang M, Kinsella TJ, Boothman DA. Radiation lethality enhancement with 9-aminocamptothecin: Comparison to other topoisomerase I inhibitors. Int J Radiat Oncol Biol Phys 1996; 36:369-76.
16. Fisher BJ, Scott C, Macdonald DR, Coughlin C, Curran WJ. Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: Results of radiation therapy oncology group trial 9507. J Clin Oncol 2001; 19:11-7.
17. Fisher B, Won M, Macdonald D, Johnson DW, Roa W. Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: Results of radiation therapy oncology group 9513. Int J Radiat Oncol Biol Phys 2002; 53:980-6.
18. Grüschow K, Klautke G, Fietkau R. Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases. Eur J Cancer 2002; 38:367-74.
19. Bernier-Chastagner V, Grill J, Doz F, Bracard S, Gentet JC, Marie-Cardine A, Luporsi E, Margueritte G, Lejars O, Laithier V, Mechinaud F, Millot F, Kalifa C, Chastagner P. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: Results of a french society of paediatric oncology phase II study. Cancer 2005; 104:2792-7.
20. Farray D, Ahluwalia MS, Snyder J, Barnett GH, Cohen BH, Suh JH, Peereboom DM. Preirradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme. Invest New Drugs 2005; 24:177-80.
21. Huang X, Traganos F, Darzynkiewicz Z. DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle and apoptosis. Cell Cycle 2003; 2:614-9.
22. Djuzenova C, Mühl B, Schakowski R, Oppitz U, Flentje M. Normal expression of DNA repair proteins, hMre11, Rad50 and Rad51 but protracted formation of Rad50 containing foci in X-irradiated skin fibroblasts from radiosensitive cancer patients. Brit J Cancer 2004; 90:2356-63.
23. Mahrhofer H, Bürger S, Oppitz U, Flentje M, Djuzenova CS. Radiation-induced DNA damage and damage repair in human tumor and fibroblast cell lines assessed by histone H2AX phosphorylation. Int J Rad Oncol Biol Phys 2006; 62:573-80.
24. Djuzenova CS, Sukhorukov VL, Klöck G, Arnold WM, Zimmermann U. Effect of electric field pulses on the viability and on the membrane-bound immunoglobulins of LPS-activated murine B-lymphocytes: Correlation with the cell cycle. Cytometry 1994; 15:35-45.
25. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273:5858-68.
26. Quick QA, Gewirtz DA. An accelerated senescence response to radiation in wild-type p53 glioblastoma multiforme cells. J Neurosurg 2006; 105:11-8.
27. O'Connor PM, Nieves-Neira W, Kerrigan D, Bertrand R, Goldman J, Kohn KW, Pommier Y. S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun 1991; 3:233-40.
28. Hsiang YH, Wu HY, Liu LF. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 1988; 48:3230-5.
29. Li LH, Fraser TJ, Olin EJ, Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res 1972; 32:2643-50.
30. Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 1973; 33:2834-6.
31. Tanaka T, Huang X, Halicka HD, Zhao H, Traganos F, Albino AP, Dai W, Darzynkiewicz Z. Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A 2007; 71:648-61.
32. Solary E, Bertrand R, Pommier Y. Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. Leuk Lymphoma 1994; 15:21-32.
33. Sathornsumetee S, Rich JN. New approaches to primary brain tumor treatment. Anticancer Drugs 2006; 17:1003-16.
34. Koster DA, Palle K, Bot ESM, Bjornsti MA, Dekker NH. Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 2007; 448:213-7.
35. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-60.
36. Morandi E, Zingaretti C, Chiozzotto D, Severini C, Semeria A, Horn W, Vaccari M, Serra R, Silingardi P, Colacci A. A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines. Cancer Lett 2006; 231:74-86.
37. Chang JY, Dethlefsen LA, Barley LR, Zhou BS, Cheng YC. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem Pharmacol 1992; 43:2443-52.
38. Naniwa J, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Shimada M, Shimogai R, Kawaguchi W, Sato S, Terakawa N. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer. Int J Gynecol Cancer 2007; 17:76-82.
39. Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR. Complex response of breast epithelial cell lines to toposomerase inhibitors. Anticancer Res 1998; 18:2919-32.
40. Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW, Pommier Y. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 1996; 56:4430-7.